Managing emissions of active pharmaceutical ingredients from manufacturing facilities: An environmental quality standard approach

Integrated Environmental Assessment and Management

Volumn 8, Issue 2, 2012, Pages 320-330

  Murray Smith, Richard J ^a   Coombe, Vyvyan T ^a   Grönlund, Marie Haag ^b   Waern, Fredrik ^b   Baird, James A ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Effluent; Environment; Manufacturing; Pharmaceutical; Risk

Indexed keywords

DRUG; DRUG RESIDUE;

ANIMAL; ARTICLE; CHEMISTRY; DRUG EFFECT; DRUG SURVEILLANCE PROGRAM; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; EUKARYOTE; FISH; FOOD CHAIN; HUMAN; INDUSTRIAL WASTE; INVERTEBRATE; MAMMAL; METABOLISM; RISK ASSESSMENT; SEWAGE; SPECIES DIFFERENCE; WATER POLLUTANT; WATER QUALITY;

ANIMALS; DRUG RESIDUES; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; EUKARYOTA; FISHES; FOOD CHAIN; HUMANS; INDUSTRIAL WASTE; INVERTEBRATES; MAMMALS; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; SEWAGE; SPECIES SPECIFICITY; WASTE DISPOSAL, FLUID; WATER POLLUTANTS, CHEMICAL; WATER QUALITY;

EID: 84863823739     PISSN: 15513793     EISSN: None     Source Type: Journal    
DOI: 10.1002/ieam.1268     Document Type: Article

References (36)

1. Ankley GT, Black MC, Garric J, Hutchinson TH, Iguchi T. 2005. A framework for assessing the hazard of pharmaceutical materials to aquatic species.
2. In: Williams RT, editor. Human pharmaceuticals: assessing the impact on aquatic ecosystems, 1st ed. Pensacola (FL): SETAC Press. p 183-238.
3. Ankley GT, Brooks BW, Huggett DB, Sumpter JP. 2007. Repeating history: Pharmaceuticals in the environment. Environ Sci Technol 41:8211-8217.
4. Ankley GT, Bennett RS, Erickson RJ, Hoff DJ, Hornung MW, Johnson RD, Mount DR, Nichols JW, RussomCL, Schmieder PK, et al. 2010. Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem 29:730-741.
5. Caldwell D, Mastrocco F, Hutchinson TH, Lange R, Heijerick D, Janssen C, Anderson PD, Sumpter JP. 2008. Derivation of an aquatic predicted no-effect concentration for the synthetic hormone, 17r-ethinyl estradiol. Environ Sci Technol 42:7046-7054.
6. Cunningham VL. 2004. Special characteristics of pharmaceuticals related to environmental fate.
7. In: Kümmerer K, editor. Pharmaceuticals in the environment: Sources, fate, effects and risks. 2nd ed. Berlin (DE): Springer- Verlag. p 13-24.
8. Eaton DL, Gilbert SG. 2008. Principles of toxicology.
9. In: Klaassen CD, editor. Casarett and Doull's Toxicology: The basic science of poisons. 7th ed. New York (NY): McGraw-Hill. 1293 p.
10. [ECHA] European Chemicals Agency. 2008. Guidance on information requirements and chemical safety assessment. Helsinki (FI): ECHA. 431 p.
11. [EMA] European Medicines Agency. 2006. Committee for Medicinal Products for Human Use (CHMP): Guideline on the environmental risk assessment of medicinal products for human use. EMEA/CPMP/SWP/4447/00. London (UK): EMA. 12 p.
12. [FDA] US Food and Drug Administration. 1998. Guidance for industry: Environmental assessment of human drug and biologics applications. Washington (DC): FDA.
13. Fick J, Lindberg RH, Parkkonen J, Arvidsson B, Tysklind M, Larsson DGJ. 2010. Therapeutic levels of levonorgestrel detected in blood plasma of fish: Results from screening rainbow trout exposed to treated sewage effluents. Environ Sci Technol 44:2661-2666.
14. Fu W, Franco A, Trapp S. 2009. Methods for estimating the bioconcentration factor of ionizable organic chemicals. Environ Toxicol Chem 2:1372-1379.
15. Gunnarsson L, Jauhiainen A, Kristiansson E, Nerman O, Larsson DG. 2008. Evolutionary conservation of human drug targets in organisms used for environmental risk assessments. Environ Sci Technol 42:5807-5813.
16. Hutchinson TH, Ankley GT, Segner H, Tyler CR. 2006. Screening and testing for endocrine disruption in fish-biomarkers as "signposts," not "traffic lights,"in risk assessment. Environ Health Perspect 114(suppl 1):106-114.
17. Kristiansson E, Fick J, Janzon A, Grabic R, Rutgersson C, Weijdegård B, Söderström H, Larsson DGJ. 2011. Pyrosequencing of antibiotic-contaminated river sediments reveals high levels of resistance and gene transfer elements. PLoS ONE 6:e17038.
18. Larsson DG, de Pedro C, Paxéus N. 2007. Effluent from drug manufacturers contains extremely high levels of pharmaceuticals. J Hazard Mater 148:751-755.
19. Lemus JA, Blanco G, Arroyo B, Martínez F, Grande J. 2009. Fatal embryo chondral damage associated with fluoroquinolones in eggs of threatened avian scavengers. Environ Pollut 157:2421-2427.
20. Li D, Yang M, Hu J, Ren L, Zhang Y, Li K. 2008. Determination and fate of oxytetracycline and related compounds in oxytetracycline production wastewater and the receiving river. Environ Toxicol Chem 27:80-86.
21. Meylan WM, Howard PH, Boethling RS, Aronson D, Printup H, Gouchie S. 1999. Improved method for estimating bioconcentration factor from octanol/water partition coeffient. Environ Toxicol Chem 18:664-672.
22. Monteiro SC, Boxall BA. 2010. Occurrence and fate of human pharmaceuticals in the environment. Rev Environ Contam Toxicol 202:53-154.
23. Nichols JW, Bonnell M, Dimitrov SD, Escher BI, Han X, Kramer NI. 2009. Bioaccumulation assessment using predictive approaches. Integr Environ Assess Manag 5:577-597.
24. Oaks JL, Gilbert M, Virani MZ, Watson RT, Meteyer CU, Rideout BA, Shivaprasad HL, Ahmed S, Chaudhry MJ, Arshad M, et al. 2004. Diclofenac residues as the cause of vulture population decline in Pakistan. Nature 427:630-633.
25. Owen SF, Giltrow E, Huggett DB, Hutchinson TH, Saye J-A, Winter MJ, Sumpter JP.2007 Comparative physiology, pharmacology and toxicology of b-blockers: mammals versus fish. Aquat Toxicol 82:145-162.
26. Richardson ML, Bowron JM. 1985. The fate of pharmaceutical chemicals in the aquatic environment. J Pharm Pharmacol 37:1-12.
27. Sanderson H, Thomsen M. 2009. Comparative analysis of pharmaceuticals versus industrial chemicals acute aquatic toxicity classification according to the United Nations classification system for chemicals. Assessment of the (Q)SAR predictability of pharmaceuticals acute aquatic toxicity and their predominant acute toxic mode-of-action. Toxicol Lett 187:84-93.
28. Schwab BW, Hayes EP, Fiori JM, Mastrocco FJ, Roden NM, Cragin D, Meyerhoff RD, D'Aco VJ, Anderson PD. 2005. Human pharmaceuticals in US surface waters: a human health risk assessment. Regul Toxicol Pharmacol 42:296-312.
29. Tarazona JV, Escher BI, Giltrow E, Sumpter J, Knacker T. 2010. Targeting the environmental risk assessment of pharmaceuticals: facts and fantasies. Integr Environ Assess Manag 6(suppl 1):603-613.
30. [USEPA] US Environmental Protection Agency. 1993. Wildlife exposure factors handbook. Volume I. Washington (DC): USEPA. EPA/600/R-93/187.
31. Van Aerle R, Pounds N, Hutchinson TH, Maddix S, Tyler C. 2002. Window of sensitivity for the estrogenic effects of ethinylestradiol in early life-stages of fathead minnow, Pimephales promelas. Ecotoxicology 11:423-434.
32. Versteeg DJ, Alder AC, Cunningham VL, Kolpin DW, Murray-Smith R, Ternes T.2005 Environmental exposure modeling and monitoring of human pharmaceutical concentrations in the environment.
33. William RT, editor. Human pharmaceuticals: assessing the impacts on aquatic ecosystems, 1st ed. Pensacola (FL): SETAC Press. p 71-110.
34. Warrington PD. 2001. Government of British Columbia, Canada, Ministry of Environment. Animal weights and their food and water requirements. [cited 2010 November 2] Available from: http://www.env.gov.bc.ca/wat/wq/reference/foodandwater.html
35. Waggott A. 1981. Trace organic substances in the River Lee. Chem Water Reuse 2:55-99.
36. Winter MJ, Owen SF, Murray-Smith RJ, Panter GH, Hetheridge MJ, Kinter LB. 2010. Using data from drug discovery and development to aid the aquatic environmental risk assessment of human pharmaceuticals: concepts, considerations and challenges. Integr Environ Assess Manag 6:38-51.